Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew (SNN) introduces QUADTRAC System and broadens ULTRABUTTON Adjustable Fixation Devices portfolio for ACL reconstruction.

Smith & Nephew (SNN) Simplifies ACL Surgery With New Offers

LONDON , March 8, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN) (NYSE:SNN), the global medical technology company, today announces it will showcase its latest Sports Medicine procedural innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2023 Annual Meeting being held in Las Vegas, NV. These include: UltraTRAC™ QUAD ACL Reconstruction Technique: New technologies combine to deliver an advanced, comprehensive procedural solution for surgeons who want to expand their ligament graft options and maximize the variety of patients they can accommodate.

Smith+Nephew to highlight procedural innovations in Sports Medicine during AAOS 2023 Annual Meeting

An uncompromising commitment to freedom of movement LONDON , March 7, 2023 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today unveils "Precision in Motion", a franchise-level value proposition spanning its Robotics, Knee, and Hip portfolios within the Orthopaedics business. It underscores Smith+Nephew's promise to deliver an uncompromising commitment to freedom of movement by focusing on three key elements– personalizing surgery, advancing efficiency, and optimizing performance.

Smith+Nephew unveils 'Precision in Motion' for its Orthopaedics Arthroplasty portfolio at AAOS 2023 Annual Meeting

LONDON , March 7, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduced the UltraTRAC™ QUAD ACL Reconstruction Technique which consists of the new QUADTRAC Quadriceps Tendon Harvest Guide System, X-WING™ Graft Preparation System and family of ULTRABUTTON Adjustable Fixation Devices. These technologies work together to provide an innovative procedural solution, expanding Smith+Nephew's ability to address surgeon graft preference.

Smith+Nephew Sports Medicine advances procedural innovation by launching the QUADTRAC™ Quadriceps Tendon Harvest Guide System and expanded family of ULTRABUTTON™ Adjustable Fixation Devices for ACL reconstruction

LONDON , March 6, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a systemic literature review and meta-analysis1 of its VISIONAIRE Patient-Specific Instrumentation (PSI) showing that its use leads to improvements in alignment accuracy, efficiency in surgical procedures, and reduction in length of hospital stay in comparison with conventional instrumentation.1 The research was published online by the Archives of Orthopaedic and Trauma Surgery. Twenty-five (25) relevant studies were included in the meta-analysis, all of which compared VISIONAIRE PSI-enabled Total Knee Arthroplasty (TKA) with conventional instrumentation-enabled TKA.

Smith+Nephew's VISIONAIRE™ Patient-Specific Instrumentation shown to improve outcome measures for total knee arthroplasty compared with conventional instrumentation

Smith & Nephew (SNN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Smith & Nephew (SNN) a New Buy Stock

Company reports top-line growth in Q4. Innovation & operational leverage finally turning the screw here.

Smith & Nephew: Orthopedic Franchise Finally Coming Along

Smith & Nephew plc (NYSE:SNN ) Q4 2022 Earnings Conference Call February 21, 2023 3:30 AM ET Company Participants Deepak Nath - CEO Anne-Francoise Nesmes - CFO Conference Call Participants Jack Reynolds-Clark - RBC Hassan Al-Wakeel - Barclays Kyle Rose - Canaccord Sebastien Jantet - Liberum David Adlington - JPMorgan Veronika Dubajova - Citi Deepak Nath So good morning, and welcome to the Smith & Nephew Full Year 2022 Results Presentation. I'm Deepak Nath, Chief Executive Officer.

Smith & Nephew plc (SNN) Q4 2022 Earnings Call Transcript

Smith & Nephew PLC (LSE:SN) reported flat annual revenue but declining margins meant operating profit fell sharply. The global medical technology company said operating profit margins slipped to 8.6% from 11.4% reflecting higher inflation in freight and logistics, the impact of China VBP, as well as sales and marketing expenditure levels returning to more normal levels.

Smith & Nephew annual profits fall as margins take a hit

Designation recognizes Vizient-contracted products that bring improvements to healthcare industry LONDON , Jan. 30, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its LEAF Patient Monitoring System has received an Innovative Technology designation from Vizient, Inc., the largest healthcare performance improvement company in the United States. Smith+Nephew exhibited the LEAF Patient Monitoring System at the Vizient Innovative Technology Exchange on October 17th in Dallas, Texas.

Smith+Nephew receives Innovative Technology designation from Vizient for LEAF™ Patient Monitoring System

The medical device industry has undergone considerable consolidation in recent years, leaving a small number of competitors, and offers long-term growth potential due to increasing longevity, an aging population and an expanding middle class.

Smith & Nephew Is Reverting to Fair Value

Smith & Nephew plc (NYSE:SNN ) Q3 2022 Results Conference Call November 3, 2022 4:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Jack Reynolds - RBC David Adlington - JPMorgan Julien Dormois - BNP Paribas Robert Davies - Morgan Stanley Chris Gretler - Credit Suisse Deepak Nath Good morning. Welcome to the Smith & Nephew Third Quarter Call.

Smith & Nephew plc (SNN) Q3 2022 Earnings Call Transcript

Smith & Nephew PLC (LSE:SN) reported a 4.8% increase in underlying revenue for the third quarter and forecast revenue growth for the full year in the middle of its previously guided range of 4%-5%.  The medical products company left its trading profit margin guidance for the year unchanged at around 17.5%, down from 18% in 2021.

Smith & Nephew says 'on track' to meet full-year revenue forecast

LONDON , Nov. 1, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of its JOURNEY II ROX Total Knee Solution – a reverse hybrid construct for total knee arthroplasty. This new procedural product solution aims to provide surgeons with the clinical advantage of an advanced bearing material and anatomic design combined with the efficiency1 and potential long-term tibia fixation of a cementless knee.

Smith+Nephew expands procedural innovation with introduction of JOURNEY™ II ROX™ Total Knee Solution

Smith & Nephew PLC (LSE:SN) shares reacted to reports from US medical technology companies that surgical procedure volumes are returning to pre-pandemic levels.

Smith & Nephew little boosted by rivals' reports of improving hip and knee sales

Medical devices manufacturer Smith & Nephew (S&N) has seen its shares sliding. I do not yet see the growth the company is targeting, but business has been recovering and its interim figures were decent if nothing special.

Smith & Nephew: Still A Buy Despite Short-Term Challenges

LONDON , Sept. 26, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the first cases for revision knee replacement utilizing its CORI◊ Surgical System.

Smith+Nephew first to market with revision knee indication on robotics platform

LONDON , Sept. 21, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it is expanding the reach of its medical education curriculum through a suite of advanced simulation technologies.

Smith+Nephew Academy expands global access to professional medical education through virtual reality and other advanced simulation technologies

LONDON , Sept. 14, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published studies supporting the use of its REGENETEN Bioinductive Implant in rotator cuff repair.

New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months

FTSE 100 constituent and medical equipment maker Smith & Nephew PLC ( SNN , Financial) ( LSE:SN. , Financial) seemed to be making progress after its 2021 results in February.

Smith & Nephew: A Medical Equipment Opportunity

LONDON , Aug. 4, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN) (NYSE: SNN), the global medical technology company, today announces that the OXINIUM Technology Tour of Change mobile exhibit will make a stop at the Pro Football Hall of Fame during its enshrinement weekend in Canton, Ohio from August 4-6. As the official joint replacement technology of the Pro Football Hall of Fame, Smith+Nephew is committed to educating retired players, their families, and the community about the differences in material, design and technology to consider when selecting a hip or knee replacement.

Smith+Nephew's OXINIUM™ Technology Tour of Change touches down at the Pro Football Hall of Fame during enshrinement weekend

Smith & Nephew plc (NYSE:SNN ) Q2 2022 Results Conference Call July 28, 2022 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America Jack Reynolds-Clark - RBC Hassan Al-Wakeel - Barclays Julien Dormois - BNP Paribas Chris Gretler - Credit Suisse David Adlington - JP Morgan Deepak Nath I'll just draw your attention to the safe harbor statement on the slide that's about to pop up in front of us. So, it's a pleasure to be reporting the results of my first full quarter as CEO and also to be meeting many of you in person for the first time.

Smith & Nephew plc (SNN) CEO Deepak Nath on Q2 2022 Results - Earnings Call Transcript

Shares in Smith & Nephew PLC (LSE:SN) plunged almost 10% after forecasting a drop in profit margins on the back of inflation and “external supply challenges". The British medical products maker now expects trading profit margin of 17.5% for 2022 compared to a 18% margin last year.

Smith & Nephew's shares slump as profit margins squeezed

LONDON , July 13, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN) (NYSE: SNN), the global medical technology company, today announces a robust line-up featuring several of its advanced joint repair solutions and a wide array of educational activities during the 2022 American Orthopaedic Society for Sport Medicine (AOSSM) Annual Meeting being held in Colorado Springs July 13-17. These include: The REGENETEN◊ Bioinductive Implant With the potential to address approximately 17 million people with rotator cuff disease in the US1, the REGENETEN implant provides a patient centric treatment that supports the body's natural healing response required to facilitate healing of rotator cuff tears.2-6  With 20+ publications7 to its name, among the most in its category, the REGENETEN implant has been shown in early studies to disrupt disease progression3-5,8, expedite return to normal activity8 and potentially reduce re-tears.9,10 The REGENETEN implant is part of Smith+Nephew's comprehensive Advanced Healing Solutions portfolio - redefining biological healing in rotator cuff repair along with expanded applications for Gluteus Medius and Achilles tears.

Smith+Nephew to showcase latest innovations for sports medicine joint repair at 2022 AOSSM Annual Meeting

LONDON , July 12, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the WOUND COMPASS™ Clinical Support App. The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation.

News for Smith & Nephew Stock (SNN)